Biofourmis, which integrates AI-based data analytics and biosensors to keep track of the development of medical treatments, has actually raised financing from one of the world’s most prominent investors. The digital therapies company, which released in Singapore and is now headquartered in Boston, announced today it closed a $100 million Series C led by SoftBank Vision Fund 2, with participation from returning investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.

The business’s last financing announcement was in Might 2019 for a $35 million Series A led by Sequoia India and MassMutual, the equity capital arm of Massachusetts Mutual Life Insurance Coverage Company.

Biofourmis’ platform integrates AI-based health analytics and wearable sensing units to assist healthcare providers gauge client progress and the effectiveness of drugs and other treatments. The company, established in 2015 by president Kuldeep Singh Rajput and managing director Wendou Niu, stated this is the biggest funding for a healthtech startup in Southeast Asia to date. In addition to Boston and Singapore, Biofourmis also has offices in Switzerland and India.

Considering that its Series A funding, Biofourmis has grown through a series of partnerships with 7 pharmaceutical companies and 10 health systems, including Novartis, AstraZeneca, and Mayo Clinic. Biofourmis likewise made numerous acquisitions, consisting of wearable biosensor start-up Biovotion and Gaido Health, a digital rehabs company for cancer patients.

The funding will be utilized to confirm and bring new digital therapeutic solutions for cardiology, respiratory, oncology and discomfort treatments to the marketplace. Biofourmis likewise prepares to broaden in the United States and Asia-Pacific markets consisting of China and Japan.

Biofourmis also stated today that it is straightening its internal operations into two verticals: Biofourmis Rehabs, which partners with business like AstraZeneca and Chugai to created software that can assist increased the efficacy of drug treatments, and Biofourmis Health, a “home health center” platform that allows health suppliers to monitor clients from another location as they shift out of intense care. Biofourmis Health concentrates on heart failure, coronary artery disease, breathing diseases and cancer.

EDBI is an investment firm linked to Singapore’s federal government, and searches for startups that can help advance the country’s industries, including healthcare. Biofourmis’ financing from EDBI is a strategic financial investment, and its innovation is being utilized in Singapore as it handles repeated outbreaks of COVID-19.

Announced last July, SoftBank Vision Fund 2 released with $108 billion to buy AI-based technology. The first Vision Fund is handling heavy losses stemming in big part from its financial investments in WeWork and Uber, so the performance of Vision Fund 2’s concentrate on markets including healthtech (its other financial investments in the space include pharmaceutical shipment startup Alto and life sciences business Karius) is being carefully viewed.

In a press declaration, SoftBank Financial investment Advisers partner Greg Moon stated, “Our company believe predictive health is the future of medicine and Biofourmis is a leader in utilizing AI and device learning-based designs to advance digital therapeutics.”

Article curated by RJ Shara from Source. RJ Shara is a Bay Area Radio Host (Radio Jockey) who talks about the startup ecosystem – entrepreneurs, investments, policies and more on her show The Silicon Dreams. The show streams on Radio Zindagi 1170AM on Mondays from 3.30 PM to 4 PM.